Back

Efficacy and safety of landiolol in patients with refractory ventricular arrhythmia and electrical storm: a single-center experience

31 August 2026 (10:15 - 10:45)
Organised by: Logo
Congress Presentation Part of: Refining arrhythmic risk and management: from prediction models to acute electrical storm therapy Drug Treatment of Ventricular Arrhythmias ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Barbara Zawislak

University Hospital of Krakow, Krakow (Poland)

2 More presentations in this session

Presentation thumbnail
Prevalence of arrhythmias and cardiac risks in adults with familial ST depression syndrome
Professor K. Vijay (Phoenix, US)
Abstract
Presentation thumbnail
Paradoxical association between programmed ventricular stimulation (PVS) induction threshold and arrhythmic events: the EP VSTIM Risk Registry
Doctor I. Mavrogenis (Marousi, GR)
Abstract

Access the full session

Session thumbnail
Refining arrhythmic risk and management: from prediction models to acute electrical storm therapy

The Event

Event poster

ESC Congress 2026

31 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Use of landiolol for acute heart rate management in critically ill cardiac patients: a retrospective single-center experience
14 March 2025
thumbnail
Congress Presentation
Safety and efficacy of bipolar RF ablation for refractory ventricular arrhythmias from the LV summit
14 April 2026
thumbnail
Webinar
Electrical storm
4 October 2022
thumbnail
Congress Presentation
Comparison between oral procainamide and mexiletine for the treatment of recurrent and refractory ventricular tachyarrhythmias.
4 April 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources